CCIA
RCKT icon

Campbell & Co Investment Adviser’s Rocket Pharmaceuticals RCKT Stock Holding History

Campbell & Co Investment Adviser’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-90,084
Closed -$601K – 1411
2025
Q1 		$601K Buy
90,084
+30,115
+50% +$298K 0.05% 605
2024
Q4 		$754K Buy
59,969
+33,718
+128% +$508K 0.06% 508
2024
Q3 		$485K Buy
26,251
+8,259
+46% +$169K 0.04% 733
2024
Q2 		$387K Buy
+17,992
New +$413K 0.03% 741
2022
Q2 		– Sell
-14,949
Closed -$237K – 873
2022
Q1 		$237K Buy
+14,949
New +$258K 0.06% 569
2021
Q4 		– Sell
-11,100
Closed -$332K – 778
2021
Q3 		$332K Buy
+11,100
New +$404K 0.11% 346

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Campbell & Co Investment Adviser's RCKT Position: Q2 2025 in Review

Campbell & Co Investment Adviser sold out of Rocket Pharmaceuticals (RCKT) in Q2 2025, closing a stake of 90,084 shares — an estimated $601K sold.

Campbell & Co Investment Adviser first reported a position in RCKT in Q3 2021 and held it in 6 quarters. The position peaked at $754K in Q4 2024. 196 funds tracked by Wall St. Rank hold RCKT as of Q2 2025.

  • Campbell & Co Investment Adviser reported no remaining Rocket Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 90,084 Rocket Pharmaceuticals shares in Q2 2025, an estimated $601K.
  • Campbell & Co Investment Adviser first reported a position in Rocket Pharmaceuticals in Q3 2021 and held it in 6 quarters.
  • Campbell & Co Investment Adviser's Rocket Pharmaceuticals position peaked at $754K in Q4 2024.
  • 196 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2025.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2025, filed 7 Aug 2025.